Immunity to Staphylococcus aureus: Implications for Vaccine Development
- PMID: 31298209
- PMCID: PMC10957185
- DOI: 10.1128/microbiolspec.GPP3-0037-2018
Immunity to Staphylococcus aureus: Implications for Vaccine Development
Abstract
Cell-mediated immunity seems to be critical for prevention and resolution of invasive S. aureus infections, but an imbalance in this immunity may also produce SIRS and death or an inadequate protective response with prolonged bacteremia and death. This dysregulation is likely at the heart of mortality and severe disease in humans. Anti-toxin antibodies may also come into play in reducing the severity of S. aureus infections, but these antibodies might also address superantigen-induced immune dysregulation. Thus, while changing intrinsic T cell responses may be therapeutically difficult, monoclonal antibodies against superantigens may have utility in addressing dysfunctional immune responses to S. aureus. The models above are hypotheses for examining, and potentially dramatically improving immune response to and safety of S. aureus vaccines.
Figures
Similar articles
-
Protection against Staphylococcus aureus Colonization and Infection by B- and T-Cell-Mediated Mechanisms.mBio. 2018 Oct 16;9(5):e01949-18. doi: 10.1128/mBio.01949-18. mBio. 2018. PMID: 30327437 Free PMC article.
-
Recombinant ESAT-6-like proteins provoke protective immune responses against invasive Staphylococcus aureus disease in a murine model.Infect Immun. 2015 Jan;83(1):339-45. doi: 10.1128/IAI.02498-14. Epub 2014 Nov 3. Infect Immun. 2015. PMID: 25368117 Free PMC article.
-
Staphylococcus aureus manganese transport protein C is a highly conserved cell surface protein that elicits protective immunity against S. aureus and Staphylococcus epidermidis.J Infect Dis. 2012 Jun;205(11):1688-96. doi: 10.1093/infdis/jis272. Epub 2012 Apr 2. J Infect Dis. 2012. PMID: 22474033 Free PMC article.
-
Staphylococcal vaccine development: review of past failures and plea for a future evaluation of vaccine efficacy not only on staphylococcal infections but also on mucosal carriage.Expert Rev Vaccines. 2013 Nov;12(11):1249-59. doi: 10.1586/14760584.2013.840091. Epub 2013 Oct 10. Expert Rev Vaccines. 2013. PMID: 24111513 Review.
-
Is there a future for a Staphylococcus aureus vaccine?Vaccine. 2012 Apr 19;30(19):2921-7. doi: 10.1016/j.vaccine.2011.11.006. Epub 2011 Nov 21. Vaccine. 2012. PMID: 22115633 Review.
Cited by
-
A randomized, double-blind study on the safety and immunogenicity of rTSST-1 variant vaccine: phase 2 results.EClinicalMedicine. 2024 Jan 5;67:102404. doi: 10.1016/j.eclinm.2023.102404. eCollection 2024 Jan. EClinicalMedicine. 2024. PMID: 38274114 Free PMC article.
-
Vaccination with VLPs Presenting a Linear Neutralizing Domain of S. aureus Hla Elicits Protective Immunity.Toxins (Basel). 2020 Jul 11;12(7):450. doi: 10.3390/toxins12070450. Toxins (Basel). 2020. PMID: 32664481 Free PMC article.
-
Development of a vaccine against Staphylococcus aureus invasive infections: Evidence based on human immunity, genetics and bacterial evasion mechanisms.FEMS Microbiol Rev. 2020 Jan 1;44(1):123-153. doi: 10.1093/femsre/fuz030. FEMS Microbiol Rev. 2020. PMID: 31841134 Free PMC article. Review.
-
Inactivation of the Sts enzymes promotes resistance to lethal Staphylococcus aureus infection.Infect Immun. 2023 Oct 17;91(10):e0026023. doi: 10.1128/iai.00260-23. Epub 2023 Sep 19. Infect Immun. 2023. PMID: 37725063 Free PMC article.
-
γδ T cell-intrinsic IL-1R promotes survival during Staphylococcus aureus bacteremia.Front Immunol. 2023 Jul 7;14:1171934. doi: 10.3389/fimmu.2023.1171934. eCollection 2023. Front Immunol. 2023. PMID: 37483624 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
